NASDAQ:CABA Cabaletta Bio (CABA) Stock Forecast, Price & News $10.09 +0.26 (+2.64%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$9.67▼$10.0950-Day Range$7.10▼$13.1652-Week Range$0.59▼$13.44Volume307,414 shsAverage Volume478,487 shsMarket Capitalization$316.42 millionP/E RatioN/ADividend YieldN/APrice Target$14.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cabaletta Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside40.4% Upside$14.17 Price TargetShort InterestBearish12.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$259,820 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.87) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector510th out of 1,006 stocksBiological Products, Except Diagnostic Industry78th out of 167 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.17, Cabaletta Bio has a forecasted upside of 40.4% from its current price of $10.09.Amount of Analyst CoverageCabaletta Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.69% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 0.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 3.0 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.Search Interest8 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,820.00 in company stock.Percentage Held by Insiders12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.12% of the stock of Cabaletta Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to grow in the coming year, from ($1.87) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cabaletta Bio (NASDAQ:CABA) StockCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Stock News HeadlinesMay 24, 2023 | finance.yahoo.comInstitutional investors in Cabaletta Bio, Inc. (NASDAQ:CABA) lost 18% last week but have reaped the benefits of longer-term growthMay 22, 2023 | finance.yahoo.comCabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional SharesJune 1, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 22, 2023 | bizjournals.comPrelude Therapeutics, Cabaletta Bio expect to raise up to $161M combined in public stock salesMay 18, 2023 | msn.comThese stocks are seeing some short squeeze action - watch out aboveMay 18, 2023 | msn.comCabaletta Bio up 1%, prices $87M offeringMay 18, 2023 | finance.yahoo.comCabaletta Bio Announces Pricing of Public Offering of Common StockMay 17, 2023 | seekingalpha.comCabaletta Bio jumps 16% as FDA clears trial for myositis candidateJune 1, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 17, 2023 | finance.yahoo.comCabaletta Bio Announces Proposed Public Offering of Common StockMay 17, 2023 | marketwatch.comThinking about buying stock in Cabaletta Bio, SNDL, Roblox, DraftKings, or Riot Platforms?May 16, 2023 | marketwatch.comCabaletta Bio Shares Rose 15% After FDA Approves IND Application for CABA-201May 16, 2023 | msn.comCabaletta Bio Jumps after New Trial PlansMay 16, 2023 | finance.yahoo.comCabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of MyositisMay 11, 2023 | marketwatch.com10-Q: CABALETTA BIO, INC.May 11, 2023 | seekingalpha.comCabaletta Bio GAAP EPS of -$0.45 beats by $0.02May 11, 2023 | msn.comRecap: Cabaletta Bio Q1 EarningsMay 11, 2023 | finance.yahoo.comCabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 3, 2023 | americanbankingnews.comShort Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Grows By 9.8%May 2, 2023 | finance.yahoo.comCabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual MeetingMay 1, 2023 | finance.yahoo.comCabaletta Bio Receives FDA Fast Track Designation for CABA-201April 25, 2023 | finance.yahoo.comGreat news for Cabaletta Bio, Inc. (NASDAQ:CABA): Insiders acquired stock in large numbers last yearApril 25, 2023 | finance.yahoo.comCabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQApril 13, 2023 | finance.yahoo.comCabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare ConferenceApril 3, 2023 | americanbankingnews.comCabaletta Bio's (CABA) "Buy" Rating Reiterated at HC WainwrightMarch 31, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Cabaletta Bio (CABA)March 31, 2023 | msn.comCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Company Calendar Last Earnings3/16/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.17 High Stock Price Forecast$18.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+40.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.20% Return on Assets-53.98% Debt Debt-to-Equity RatioN/A Current Ratio10.29 Quick Ratio10.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.92 per share Price / Book3.46Miscellaneous Outstanding Shares31,360,000Free Float27,490,000Market Cap$316.42 million OptionableNot Optionable Beta2.54 Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 61)Co-Founder, Chairman, CEO & Pres Comp: $904.13kDr. Gwendolyn K. Binder Ph.D. (Age 47)Pres of Science & Technology Comp: $654.51kDr. David J. Chang FACR (Age 59)M.D., M.P.H., Chief Medical Officer Comp: $656.29kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 45)Chief Financial Officer Dr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 42)Gen. Counsel & Sec. Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief HR OfficerMore ExecutivesKey CompetitorsScholar RockNASDAQ:SRRKKodiak SciencesNASDAQ:KODVigil NeuroscienceNASDAQ:VIGLMonte Rosa TherapeuticsNASDAQ:GLUESOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsGwendolyn BinderSold 22,000 sharesTotal: $259,820.00 ($11.81/share)Perceptive Advisors LLCBought 407,323 shares on 5/16/2023Ownership: 2.311%Geode Capital Management LLCSold 11,415 shares on 5/16/2023Ownership: 0.746%Jane Street Group LLCBought 63,757 shares on 5/16/2023Ownership: 0.331%State Street CorpSold 5,200 shares on 5/16/2023Ownership: 0.263%View All Insider TransactionsView All Institutional Transactions CABA Stock - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price forecast for 2023? 5 Wall Street research analysts have issued 1-year target prices for Cabaletta Bio's shares. Their CABA share price forecasts range from $10.00 to $18.00. On average, they anticipate the company's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 40.4% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2023? Cabaletta Bio's stock was trading at $9.25 at the beginning of the year. Since then, CABA stock has increased by 9.1% and is now trading at $10.09. View the best growth stocks for 2023 here. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) posted its earnings results on Thursday, March, 16th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. What is Cabaletta Bio's stock symbol? Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA." Who are Cabaletta Bio's major shareholders? Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (13.62%), Commodore Capital LP (6.22%), Jennison Associates LLC (2.65%), Perceptive Advisors LLC (2.31%), BlackRock Inc. (0.79%) and Geode Capital Management LLC (0.75%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cabaletta Bio's stock price today? One share of CABA stock can currently be purchased for approximately $10.09. How much money does Cabaletta Bio make? Cabaletta Bio (NASDAQ:CABA) has a market capitalization of $316.42 million. The company earns $-52,970,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. How can I contact Cabaletta Bio? Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The official website for the company is www.cabalettabio.com. The company can be reached via phone at 267-759-3100 or via email at investors@cabalettabio.com. This page (NASDAQ:CABA) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.